Investment Rating - The report indicates a positive outlook for the company, with an expected net profit of 2.02 billion to 2.35 billion yuan for 2025, representing a year-on-year growth of 21.05% to 40.83% [2][3]. Core Insights - The company's performance in 2025 is primarily driven by strong results in its asset management business, despite a decline in its core operations [2][15]. - For the first three quarters of 2025, the company reported revenues of 1.069 billion yuan, with a net profit of 1.589 billion yuan, indicating that total operating costs exceeded revenues [4][5]. - The total assets under management reached 24.122 billion yuan by the end of Q3 2025, highlighting the significant contribution of asset management to the company's profitability [8]. Financial Performance - The expected net profit for 2025 is projected to be between 2.02 billion and 2.35 billion yuan, with a growth rate of 21.05% to 40.83% compared to the previous year [2][3]. - The company’s investment income for the first three quarters of 2025 was 562 million yuan, with fair value changes contributing 1.251 billion yuan, totaling over 1.8 billion yuan in investment-related income [5]. - The company holds trading financial assets worth 10.362 billion yuan, primarily in wealth management products, and other financial assets totaling 10.245 billion yuan, including hedge funds and private equity investments [6][8]. Core Business Performance - The iHealth product line, which includes smart medical devices, has seen a significant decline in revenue, with a 50% drop in the first half of 2025 compared to the previous year [10][11]. - The total revenue from iHealth products for the first three quarters of 2025 was reported at 601 million yuan, reflecting a 49% year-on-year decrease [11][12]. Market Position - The company's price-to-book (PB) ratio is currently at 0.89, indicating that it is trading below its book value, which may attract investors looking for undervalued assets [14]. - The company has substantial cash-like assets totaling 27.6 billion yuan, with short-term borrowings of only 2.334 billion yuan, suggesting a strong liquidity position [14].

Core Viewpoint - Oriental Bio has faced significant operational challenges, including two consecutive years of losses and recent management changes, which have raised concerns about its future performance and strategic direction [1][2][3]. Financial Performance - Oriental Bio reported a dramatic decline in revenue, with 2023 revenue plummeting by 90.65% to 820 million yuan, and a net loss of 398 million yuan, marking a 119.23% year-over-year decrease [3][4]. - In 2021, the company achieved record revenues of 10.169 billion yuan, a 211.43% increase from the previous year, and a net profit of 4.92 billion yuan, reflecting a 193.33% growth [3]. - The company’s performance was heavily influenced by its COVID-19 testing products, which contributed significantly to its revenue during the pandemic [4]. Management Changes - The company has experienced a shift in its management team, with two board members resigning within a month, raising questions about leadership stability [1]. Business Expansion and Strategy - Oriental Bio is actively expanding its business, particularly in the U.S. market, through acquisitions and the establishment of production bases for chronic disease monitoring and animal diagnostics [5][6]. - The company has diversified its portfolio by adding an animal vaccine business, aiming to create a dual-track business model that includes both human and animal health [5]. Legal Challenges - The company is currently facing a significant lawsuit in the U.S., with claims exceeding 1 billion USD related to alleged contract violations, which could impact its financial stability [6]. Shareholder Actions - In response to ongoing losses and to bolster market confidence, Oriental Bio initiated a share buyback program, committing to repurchase shares worth between 25 million and 50 million yuan [7].